FILGRASTIM
Severe Aplastic Anemia
Masonic Cancer Center, University of Minnesotaprotein_peptidePhase 2Active
B
62/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 47/ 100
- Competitive Position
- 95/ 100
Competitive context
9 Active assets in the Severe Aplastic Anemia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Fludarabine Masonic Cancer Center, University of Minnesota | Phase 2 | BB |
Cyclophosphamide Masonic Cancer Center, University of Minnesota | Phase 2 | B |
Busulphan Masonic Cancer Center, University of Minnesota | Phase 2 | B |
TACROLIMUS West Virginia University | Phase 2 | B |
METHOTREXATE University of California, San Francisco | Phase 2 | B |
View all 18 →
Same molecule, other indications
FILGRASTIM is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →